XCEED - Dr. Reddy’s Customer Service Platform for our API Customers
Dr. Reddy's provides its customers with a superior service experience through well-defined processes and a digital engagement platform called XCEED. For our API customers, XCEED enables the customer to manage the complete inquiry and procurement process of Dr. Reddy's generic active pharmaceutical ingredients (APIs) in real-time. In addition, with its advanced B2B customer service portal features, XCEED is entirely focused on significantly increasing the operational efficiency in doing business with Dr. Reddy's.
We have designed the XCEED platform by gathering insights and understanding the customers' pain points through surveys, market research, and conversations with our customers. As a result, XCEED is created to seamlessly cater to the customers' needs by providing an advanced customer experience and facilitating collaboration.
XCEED gives instant access to an industry-leading portfolio that spans a wide range of indications and complex molecules such as steroids, peptides, or highly potent APIs (HPAPI). From ordering samples to submitting and tracking their orders, XCEED provides convenience and transparency to our customers by providing a centralized platform to interact with Dr. Reddy's interdisciplinary customer service team that helps in the timely delivery of the APIs.
Get Started
Re-imagine API sourcing with XCEED Dr. Reddy’s Customer Engagement Platform
Get product details and insights
Submit service requests and orders
Track order and get updates
Get personalized support
Key Features of XCEED Customer service:
Access to technical documents and whitepapers – Knowledge Enhancement
Option to raise any type of service request – Everything, Anytime
Direct notification and update on requests and orders – Most convenient way
Dedicated customer service team supporting all transactions – Faster turnaround
Testimonial
“The information on XCEED is well structured and easy to find. This makes my life much easier” -
Associate Director, Global Procurement, French generics company.
“The information on XCEED is well structured and easy to find. This makes my life much easier” -
Associate Director, Global Procurement, French generics company.
国別の要件がある場合は、お手伝いいたします。
FAQs
An active pharmaceutical ingredient is defined in ICH Q7 as “any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.”
-
API manufacturers are expected to apply CGMPs to the API process beginning with the use of starting materials, and to validate critical process steps that impact the quality and purity of the final API. Controls over material quality are expected to increase as the process approaches the final API. The level of control needed is highly dependent on the manufacturing process and increases throughout the process as it proceeds from early intermediate steps to final isolation and purification steps. The appropriate level of control depends on the risk or criticality associated with each specific process step.
An API process is a related series of operations which result in the preparation of an active pharmaceutical ingredient. Major operations or steps in an API process may include multi-step chemical synthesis and fermentation, purification, crystallization, drying, milling, packing, labelling, and testing. The final API the progresses towards appropriate characterization and analytical techniques.
-
Each country will have its regulatory authority that continuously monitors the drug development process, licensing, registrations, marketing, and labelling of the products. Some of the notable regulatory bodies are as follows: USFDA(USA), MHRA(UK), TGA(Australia), CDSCO(India), etc.
The quality of APIs has a significant effect on the efficacy and the safety of medications. Poorly manufactured or adulterated APIs are associated with health issues, illness, or death. So, to ensure the quality and prevent the defects of APIs, regulatory bodies impose stringent rules & screen the APIs thoroughly to ensure medication quality as per the regulatory standards. Violating any of these regulatory standards or procedures can result in huge fines.
-
The global API market size is expected to reach USD 247.3 billion by 2025 from USD 185.3 billion in 2020, at a CAGR of 5.7%. Market growth will be steered by factors such as rising drug R&D, chronic diseases, the demand for generics, and the increasing uptake of biopharmaceuticals.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。